IHC revealed that treatment with the STING agonists increased infiltration of CD3+ T cells, CD4+ Th cells, and CD8+ cytotoxic T cells, as well as PD-1–expressing cells, into the tumor (Figure 3, A and B, and Supplemental Figure 2, D and E). Here, STING1 is linked to neoplasm.